BUGVI 5mg / ml powder for infusion dispersion medication leaflet

L01CD01 paclitaxel • Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Taxanes

Paclitaxel is a chemotherapy agent used in the treatment of various cancers, including breast, ovarian, and lung cancer. It works by inhibiting cell division, stabilizing microtubules, and preventing chromosome separation during mitosis.

The medication is administered intravenously, as directed by a doctor, usually once every three weeks. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.

Patients should be aware of potential side effects, such as nausea, hair loss, or peripheral neuropathy. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, hair loss, and peripheral neuropathy. In rare cases, severe reactions such as myelosuppression or allergic reactions may occur. Patients should be informed of these risks before use.

General data about BUGVI 5mg / ml

Substance: paclitaxel

Date of last drug list: 01-06-2025

Commercial code: W70595001

Concentration: 5mg / ml

Pharmaceutical form: powder for infusion dispersion

Quantity: 1

Product type: generic

Price: 1786.05 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: STADA ARZNEIMITTEL AG - AUSTRIA

Holder: STADA M&D S.R.L. - ROMANIA

Number: 15619/2024/01

Shelf life: 3 years-after packing for marketing;Dupa reconstituire - it is used immediately

Concentrations available for paclitaxel

5mg/ml, 6mg/ml

Other substances similar to paclitaxel

Compensation lists for BUGVI 5mg / ml STADA

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

1786.05 RON

1786.05 RON

0.00 RON